These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 29935947)

  • 1. Add-on therapy with traditional Chinese medicine: An efficacious approach for lipid metabolism disorders.
    Zhang Y; Kishi H; Kobayashi S
    Pharmacol Res; 2018 Aug; 134():200-211. PubMed ID: 29935947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alteration of lipid metabolism in chronic kidney disease, the role of novel antihyperlipidemic agents, and future directions.
    Sudhakaran S; Bottiglieri T; Tecson KM; Kluger AY; McCullough PA
    Rev Cardiovasc Med; 2018 Sep; 19(3):77-88. PubMed ID: 31054556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacology of Nutraceuticals with Lipid Lowering Properties.
    Poli A; Visioli F
    High Blood Press Cardiovasc Prev; 2019 Apr; 26(2):113-118. PubMed ID: 30877602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. News from ESC congress 2019: New ESC/EAS guidelines for dyslipidaemia management published.
    Stock J
    Atherosclerosis; 2019 Dec; 291():124-126. PubMed ID: 31668350
    [No Abstract]   [Full Text] [Related]  

  • 5. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk.
    ; ;
    Atherosclerosis; 2019 Nov; 290():140-205. PubMed ID: 31591002
    [No Abstract]   [Full Text] [Related]  

  • 6. Hypolipidemic drugs in elderly subjects: Indications and limits.
    Gazzola K; Vigna GB
    Nutr Metab Cardiovasc Dis; 2016 Dec; 26(12):1064-1070. PubMed ID: 27522161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical controversies in lipid management.
    Tziomalos K
    Panminerva Med; 2015 Jun; 57(2):65-70. PubMed ID: 25669164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of DLT-SML on Chronic Stable Angina Through Ameliorating Inflammation, Correcting Dyslipidemia, and Regulating Gut Microbiota.
    Zhao X; Chen Y; Li L; Zhai J; Yu B; Wang H; Yang D; Wang Q; Chang Y; Li J; Zhang P; Zhang H; Li Y
    J Cardiovasc Pharmacol; 2021 Feb; 77(4):458-469. PubMed ID: 33657052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-intensity lipid-lowering regimens in patients with stable coronary artery disease: the intriguing question of all-cause mortality.
    Danchin N; Simon T
    Eur Heart J Cardiovasc Pharmacother; 2020 Sep; 6(5):328-330. PubMed ID: 31539045
    [No Abstract]   [Full Text] [Related]  

  • 10. From Lipids to Inflammation: New Approaches to Reducing Atherosclerotic Risk.
    Shapiro MD; Fazio S
    Circ Res; 2016 Feb; 118(4):732-49. PubMed ID: 26892970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of the non-fasting lipid profile for lipid-lowering therapy in clinical practice - point of view.
    de Vries M; Klop B; Castro Cabezas M
    Atherosclerosis; 2014 Jun; 234(2):473-5. PubMed ID: 24814412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipids and antithrombotic treatment.
    Agewall S
    Eur Heart J Cardiovasc Pharmacother; 2020 Apr; 6(2):71. PubMed ID: 32176294
    [No Abstract]   [Full Text] [Related]  

  • 13. Dyslipidemia Part 2: Review of Dyslipidemia Treatment in Patients With Noncoronary Vascular Disease.
    Gonzalez L; Helkin A; Gahtan V
    Vasc Endovascular Surg; 2016 Feb; 50(2):119-35. PubMed ID: 26983668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in the Study of Marine Products with Lipid-Lowering Properties.
    Zhao J; Cao Q; Xing M; Xiao H; Cheng Z; Song S; Ji A
    Mar Drugs; 2020 Jul; 18(8):. PubMed ID: 32726987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Actions of metformin and statins on lipid and glucose metabolism and possible benefit of combination therapy.
    van Stee MF; de Graaf AA; Groen AK
    Cardiovasc Diabetol; 2018 Jun; 17(1):94. PubMed ID: 29960584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New trials in the scene of cardiovascular disease: innovation, controversy, and reassurance.
    Badimon L
    Cardiovasc Res; 2021 Mar; 117(4):e52-e54. PubMed ID: 33615348
    [No Abstract]   [Full Text] [Related]  

  • 17. Managing the dyslipidemia of metabolic syndrome: beyond statin therapy.
    Jialal I; Smith G
    Metab Syndr Relat Disord; 2012 Jun; 10(3):159-60. PubMed ID: 22568574
    [No Abstract]   [Full Text] [Related]  

  • 18. The effects of a nutraceutical combination on plasma lipids and glucose: A systematic review and meta-analysis of randomized controlled trials.
    Pirro M; Mannarino MR; Bianconi V; Simental-Mendía LE; Bagaglia F; Mannarino E; Sahebkar A
    Pharmacol Res; 2016 Aug; 110():76-88. PubMed ID: 27157250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coronary artery disease: Risk stratification and patient selection for more aggressive secondary prevention.
    Schiele F; Ecarnot F; Chopard R
    Eur J Prev Cardiol; 2017 Jun; 24(3_suppl):88-100. PubMed ID: 28618915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipid Metabolism and Emerging Targets for Lipid-Lowering Therapy.
    Gaudet D; Drouin-Chartier JP; Couture P
    Can J Cardiol; 2017 Jul; 33(7):872-882. PubMed ID: 28365054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.